Telomir Pharmaceuticals, Inc. Common Stock (TELO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Telomir Pharmaceuticals, Inc. Common Stock (TELO) has a cash flow conversion efficiency ratio of -0.357x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.77 Million) by net assets ($4.96 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Telomir Pharmaceuticals, Inc. Common Sto market capitalisation for the company's overall valuation and market capitalisation.
Telomir Pharmaceuticals, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Telomir Pharmaceuticals, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Telomir Pharmaceuticals, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Telomir Pharmaceuticals, Inc. Common Stock ranked by their cash flow conversion efficiency. See cash flow to debt ratio of Telomir Pharmaceuticals, Inc. Common Sto to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
INSUN Environmental New Technology Co. Ltd
KQ:060150
|
0.010x |
|
Dual Co Ltd
KO:016740
|
0.028x |
|
GBM Resources Limited
AU:GBM
|
-0.031x |
|
Harn Len Corporation Bhd
KLSE:7501
|
-0.012x |
|
AAC Clyde Space AB (publ)
ST:AAC
|
-0.034x |
|
Ko Ja Cayman Co Ltd
TW:5215
|
0.019x |
|
Grimoldi SA
BA:GRIM
|
0.108x |
|
Tycoons Group Enterprise Co Ltd
TW:2022
|
-0.033x |
Annual Cash Flow Conversion Efficiency for Telomir Pharmaceuticals, Inc. Common Stock (2021–2025)
The table below shows the annual cash flow conversion efficiency of Telomir Pharmaceuticals, Inc. Common Stock from 2021 to 2025. View current stock price of Telomir Pharmaceuticals, Inc. Common Sto for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $5.91 Million | $-3.69 Million | -0.624x | +92.09% |
| 2024-09-30 | $643.04K | $-5.07 Million | -7.885x | -602.39% |
| 2023-09-30 | $3.44 Million | $-3.86 Million | -1.123x | -324.51% |
| 2022-09-30 | $-937.28K | $-468.66K | 0.500x | -65.19% |
| 2021-09-30 | $-83.13K | $-119.40K | 1.436x | -- |
About Telomir Pharmaceuticals, Inc. Common Stock
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macu… Read more